trial

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCTId NCT00505765
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 63 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2009-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
63 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2007-07
Primary completion
2009-04
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AL-108

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
University of Maryland, Baltimore CountyCollaborator
Washington University School of MedicineCollaborator
Massachusetts General HospitalCollaborator
Nathan Kline Institute for Psychiatric ResearchCollaborator
Columbia UniversityCollaborator
Duke UniversityCollaborator
Beth Israel Deaconess Medical CenterCollaborator

Investigators

1
Daniel C. Javitt, MD, PhDPrincipal Investigator

Sites

8 total
Los Angeles, United StatesCatonsville, United StatesBoston, United StatesBoston, United StatesSt Louis, United StatesNew York, United StatesOrangeburg, United StatesDurham, United States

Linked catalysts

1
A Multicenter Study of NAP (AL-108) in Schizophrenia — primary completion2009-04

Facts & assertions

4 sourced
Enrollment
63
Phase
PHASE2
Primary Completion Date
2009-04
Status
COMPLETED
relationships
The graph out of here
drug
AL-108
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
University of Maryland, Baltimore County
company
Washington University School of Medicine
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Daniel C. Javitt, MD, PhD
person